RAPT Therapeutics Net Income From Continuing Ops Over Time
| RAPT Stock | USD 57.68 0.10 0.17% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out RAPT Therapeutics Performance and RAPT Therapeutics Correlation. Is there potential for Biotechnology market expansion? Will RAPT introduce new products? Factors like these will boost the valuation of RAPT Therapeutics. Anticipated expansion of RAPT directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about RAPT Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of RAPT Therapeutics is measured differently than its book value, which is the value of RAPT that is recorded on the company's balance sheet. Investors also form their own opinion of RAPT Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is RAPT Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because RAPT Therapeutics' market value can be influenced by many factors that don't directly affect RAPT Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between RAPT Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding RAPT Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, RAPT Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare RAPT Therapeutics and related stocks such as Neumora Therapeutics, Bicycle Therapeutics, and Omeros Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NMRA | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (237.3 M) | (130.9 M) | (235.9 M) | (243.8 M) | (219.4 M) | (230.4 M) |
| BCYC | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (16.3 M) | (21.8 M) | (30.6 M) | (51 M) | (66.8 M) | (112.7 M) | (180.7 M) | (169 M) | (152.1 M) | (144.5 M) |
| OMER | (28.5 M) | (28.5 M) | (38.4 M) | (52.3 M) | (73.7 M) | (75.1 M) | (66.7 M) | (53.5 M) | (126.8 M) | (84.5 M) | (138.1 M) | (191.5 M) | (182 M) | (181.7 M) | (182.6 M) | (164.4 M) | (172.6 M) |
| ADCT | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (123.1 M) | (116.5 M) | (246.3 M) | (230 M) | (155.8 M) | (178.5 M) | (157.8 M) | (142.1 M) | (149.2 M) |
| LXRX | (116.2 M) | (116.2 M) | (110.2 M) | (104.1 M) | (100.3 M) | (4.7 M) | (141.4 M) | (129.1 M) | (120.5 M) | 130.1 M | (58.6 M) | (87.8 M) | (101.9 M) | (157.9 M) | (200.4 M) | (180.4 M) | (171.3 M) |
| ALMS | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (155 M) | (294.2 M) | (264.8 M) | (278.1 M) |
| FULC | (23 M) | (23 M) | (23 M) | (23 M) | (23 M) | (23 M) | (23 M) | (23 M) | (32.6 M) | (82.7 M) | (70.8 M) | (80.8 M) | (109.9 M) | (98.7 M) | (9.7 M) | (8.8 M) | (9.2 M) |
| FDMT | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (9.6 M) | (49.3 M) | (56.7 M) | (71.3 M) | (107.5 M) | (95.9 M) | (160.9 M) | (144.8 M) | (137.5 M) |
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (6.8 M) | (147 M) | (180.3 M) | (243.4 M) | (234 M) | (229.4 M) | (187.4 M) | (56.5 M) | (50.9 M) | (53.4 M) |
| KALV | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (24.8 M) | (18.6 M) | (15.8 M) | (20.8 M) | (29.1 M) | (46.2 M) | (82.3 M) | (92.9 M) | (126.6 M) | (183.4 M) | (24.8 M) | (26.1 M) |
RAPT Therapeutics and related stocks such as Neumora Therapeutics, Bicycle Therapeutics, and Omeros Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| RAPT Therapeutics | RAPT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 561 Eccles Avenue, |
| Exchange | NASDAQ Exchange |
USD 57.68
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.